Perspective Therapeutics Enters Material Definitive Agreement
Ticker: CATX · Form: 8-K · Filed: May 29, 2024 · CIK: 728387
Sentiment: neutral
Topics: material-agreement, corporate-action
TL;DR
PTX signed a big deal, filing shows. Could be a game-changer.
AI Summary
Perspective Therapeutics, Inc. announced on May 24, 2024, that it entered into a material definitive agreement. The company, formerly known as Isoray, Inc., is involved in the surgical and medical instruments and apparatus industry. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
This filing indicates a significant new development for Perspective Therapeutics, Inc., potentially impacting its business operations and future strategy.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks and opportunities that are not yet fully understood.
Key Numbers
- 001-33407 — SEC File Number (Identifier for the company's filings)
- 41-1458152 — IRS Employer Identification No. (Tax identification number)
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Registrant
- Isoray, Inc. (company) — Former company name
- May 24, 2024 (date) — Date of earliest event reported
- 2401 Elliott Avenue, Suite 320 (location) — Business address
- Seattle (location) — City of business address
FAQ
What is the nature of the material definitive agreement entered into by Perspective Therapeutics, Inc.?
The filing states that Perspective Therapeutics, Inc. entered into a material definitive agreement on May 24, 2024, but the specific details of the agreement are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 24, 2024.
What was Perspective Therapeutics, Inc. formerly known as?
Perspective Therapeutics, Inc. was formerly known as Isoray, Inc.
What is the primary business of Perspective Therapeutics, Inc. according to the SIC code?
According to the Standard Industrial Classification (SIC) code 3841, the primary business of Perspective Therapeutics, Inc. is Surgical & Medical Instruments & Apparatus.
Where is Perspective Therapeutics, Inc. located?
Perspective Therapeutics, Inc. is located at 2401 Elliott Avenue, Suite 320, Seattle, WA 98121.
Filing Stats: 1,740 words · 7 min read · ~6 pages · Grade level 12.5 · Accepted 2024-05-29 16:05:13
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
- $1.51 — ice to the investors for the Shares was $1.51 per Share, and the price to the investo
- $1.509 — vestors for the Pre-Funded Warrants was $1.509 per Pre-Funded Warrant, which represent
- $80 m — ny from the Offering were approximately $80 million, before underwriting discounts an
Filing Documents
- catx-20240524.htm (8-K) — 55KB
- catx-ex1_1.htm (EX-1.1) — 269KB
- catx-ex4_1.htm (EX-4.1) — 143KB
- catx-ex5_1.htm (EX-5.1) — 22KB
- catx-ex99_1.htm (EX-99.1) — 19KB
- img170034268_0.jpg (GRAPHIC) — 27KB
- img236230851_0.jpg (GRAPHIC) — 57KB
- 0000950170-24-065920.txt ( ) — 819KB
- catx-20240524.xsd (EX-101.SCH) — 23KB
- catx-20240524_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On May 24, 2024, Perspective Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with BofA Securities, Inc., as representative of the underwriters named therein (the "Underwriters"), in connection with its previously announced underwritten offering (the "Offering") of 51,515,880 shares (the "Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock") and, in lieu of Shares to certain investors, pre-funded warrants (the "Pre-Funded Warrants") to purchase 1,464,252 shares of Common Stock. The price to the investors for the Shares was $1.51 per Share, and the price to the investors for the Pre-Funded Warrants was $1.509 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each such Pre-Funded Warrant. The Offering closed on May 29, 2024. BofA Securities, Inc., Oppenheimer & Co. Inc. and RBC Capital Markets, LLC acted as joint book-running managers for the Offering and B. Riley Securities, Inc. acted as a co-manager for the Offering. JonesTrading Institutional Services LLC acted as a financial advisor for the Offering. The gross proceeds to the Company from the Offering were approximately $80 million, before underwriting discounts and commissions and estimated expenses of the Offering. The Company intends to use the net proceeds from the Offering for: (i) the continued clinical development of VMT--NET, VMT-01/02 and PSV359; (ii) the continued development of PSV40X and additional preclinical product candidates as well as broader development platform; and (iii) the build out, operation and expansion of manufacturing facilities, as well as for working capital and other general corporate purposes. A portion of the net proceeds may also be used to acquire, license or invest in complementary products, technologies, intellectual property or businesses, although the Compan
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve estimates, assumptions, risks and uncertainties. Forward-looking statements include, but are not limited to, statements related to the anticipated use of proceeds from the Offering. The risks and uncertainties relating to the Company and the Offering include general market conditions as well as other risks detailed from time to time in the Company's Securities and Exchange Commission filings, including in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, its Current Reports on Form 8-K and the prospectus supplement dated May 24, 2024 relating to the Offering. These documents contain important factors that could cause actual results to differ from current expectations and from forward-looking statements contained in this Current Report on Form 8-K. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and the Company undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this Current Report on Form 8-K.
01 Other Events
Item 8.01 Other Events. The Company issued a press release announcing the Offering on May 24, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1* Underwriting Agreement, by and between Perspective Therapeutics, Inc. and BofA Securities, Inc., as representative of the underwriters named therein, dated May 24, 2024. 4.1 Form of Pre-Funded Warrant. 5.1 Opinion of Hogan Lovells US LLP. 23.1 Consent of Hogan Lovells US LLP (contained in Exhibit 5.1). 99.1 Press Release issued by Perspective Therapeutics, Inc., dated May 24, 2024 announcing the pricing of the Offering. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request. The Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or exhibits so furnished.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: May 29, 2024 By: /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer